We are live on
!
Find out more
SGA
Sector Gamma AS Portfolio holdings
AUM
$423M
1-Year Est. Return
17.56%
This Fund
S&P 500
This Quarter
Est. Return
-3.59%
1 Year Est. Return
+17.56%
3 Year Est. Return
+28.73%
5 Year Est. Return
+52.48%
10 Year Est. Return
+238.19%
AUM
$501M
AUM Growth
-$63.3M
(-11%)
Cap. Flow
-$45.4M
Cap. Flow
% of AUM
-9.05%
Top 10 Holdings %
Top 10 Hldgs %
56.05%
Holding
39
New
2
Increased
14
Reduced
13
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$27.2M |
| 2 |
Dentsply Sirona
XRAY
|
+$15.5M |
| 3 |
Qiagen
QGEN
|
+$8.93M |
| 4 |
Cardinal Health
CAH
|
+$8.39M |
| 5 |
Boston Scientific
BSX
|
+$7.36M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$21.6M |
| 2 |
Gilead Sciences
GILD
|
+$14.5M |
| 3 |
Henry Schein
HSIC
|
+$12.3M |
| 4 |
Revvity
RVTY
|
+$10.4M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$9.84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PDCO
26
DELISTED
Patterson Companies, Inc.
PDCO
| $5.14M | 1.03% |
170,547
+28,804
| +20% | +$874K |
|
|
SAGE
27
DELISTED
Sage Therapeutics
SAGE
| $4.91M | 0.98% |
110,767
+20,029
| +22% | +$919K |
|
|
MRTX
28
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.6M | 0.92% |
+26,000
| New | +$4.18M |
|
29
Novavax
NVAX
$1.3B
| $2.29M | 0.46% |
11,044
-2,582
| -19% | -$569K |
|
|
30
Alnylam Pharmaceuticals
ALNY
$36.4B
| – | – |
-58,017
| Closed | -$9.84M |
|
31
Aurinia Pharmaceuticals
AUPH
$1.96B
| – | – |
-234,916
| Closed | -$3.04M |
|
32
BioMarin Pharmaceuticals
BMRN
$11.4B
| – | – |
-68,964
| Closed | -$5.75M |
|
|
HOLX
33
DELISTED
Hologic
HOLX
| – | – |
-117,738
| Closed | -$7.86M |
|
|
34
Henry Schein
HSIC
$9.82B
| – | – |
-165,721
| Closed | -$12.3M |
|
35
Johnson & Johnson
JNJ
$599B
| – | – |
-30,000
| Closed | -$4.94M |
|
36
LivaNova
LIVN
$4.35B
| – | – |
-14,803
| Closed | -$1.25M |
|
37
Perrigo
PRGO
$1.47B
| – | – |
-204,732
| Closed | -$9.39M |
|
38
Regeneron Pharmaceuticals
REGN
$70.5B
| – | – |
-4,876
| Closed | -$2.72M |
|
|
39
Revvity
RVTY
$11.9B
| – | – |
-67,661
| Closed | -$10.4M |
|
Similar funds
AFWM
MP
DS
RS
DF
OGM
CPIM
MPPLM
Sector Gamma AS's Q3 2021 Portfolio in Review
As of Q3 2021, Sector Gamma AS held 39 positions worth $501M, down 11% from $565M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Sector Gamma AS withdrew a net $45.4M in Q3 2021, closing 10 positions and reducing 13 holdings. Its most notable exit was Henry Schein, an estimated $12.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Sector Gamma AS opened a new position in Dentsply Sirona worth $14.6M.
- Sector Gamma AS's largest Q3 2021 buy was Dentsply Sirona: 251,330 shares worth $14.6M.
- Sector Gamma AS added most to Merck in Q3 2021, an estimated $27.2M increase.
- Sector Gamma AS's biggest Q3 2021 reduction was Pfizer, cutting an estimated $21.6M.
- Sector Gamma AS fully exited Henry Schein in Q3 2021, selling an estimated $12.3M.
- Sector Gamma AS's ten largest holdings make up 56% of its $501M portfolio in Q3 2021.
- Sector Gamma AS opened 2 new positions and closed 10 in Q3 2021.
- Sector Gamma AS's portfolio value fell 11% quarter-over-quarter to $501M.
Based on Sector Gamma AS's 13F filing for Q3 2021, filed 29 Oct 2021.